Table 4. The selected genes are found to be altered in defined cancer studies.
| Cancer type | Data set size | % Genes alteration |
|---|---|---|
| Pancreatic Cancer (UTSW, Nat Commun 2015) | 109 patients, 109 samples | 55 % |
| Uterine Corpus Endometrial Carcinoma (TCGA, PanCancer Atlas) | 509 patients / 509 samples | 40 % |
| Ovarian Serous Cystadenocarcinoma (TCGA) | 316 patients, 316 samples | 40 % |
| Neuroendocrine Prostate Cancer (Trento/Cornell/Broad 2016) | 77 patients, 107 samples | 46 % |
| Breast Invasive Carcinoma (TCGA) | 963 patients, 963 samples | 30 % |
| Liver Hepatocellular Carcinoma (TCGA) | 373 patients, 373 samples | 31 % |
| Stomach Adenocarcinoma (TCGA, Nature 2014) | 287 patients, 287 samples | 33 % |
| Sarcoma (TCGA) | 252 patients, 254 samples | 35 % |
The selected genes retrieved from DisGeNet analysis have been analyzed with cBioPortal. We reported data referred to cancer samples where the selected genes were found altered in at least 30% of cases. The size of data set and the percentage of gene alterations are shown.